In preclinical models of ischemia [80] and TBI [81,82], SFN significantly reduced blood–brain barrier disruption and brain edema, restored AQP4 levels, decreased infarct size and neurological deficit, and, when administered within the first hours after TBI, markedly improved spatial and working memory. Here, AQP4 is linked to ischemia.